Proteasome inhibition measurements: clinical application.

@article{Lightcap2000ProteasomeIM,
  title={Proteasome inhibition measurements: clinical application.},
  author={Eric S. Lightcap and Teresa A McCormack and Christine S Pien and Vincent Chau and Julian Adams and Peter J. Elliott},
  journal={Clinical chemistry},
  year={2000},
  volume={46 5},
  pages={
          673-83
        }
}
BACKGROUND PS-341, a selective inhibitor of the proteasome, currently is under evaluation as an anticancer agent in multiple phase I clinical trials. In animal-model studies, PS-341 was rapidly removed from the vascular compartment and distributed widely, quickly approaching the limits of detection. An accurate pharmacodynamic assay has been developed as an alternative or complement to pharmacokinetic measurements. METHODS Fluorogenic kinetic assays for both the chymotryptic and tryptic… CONTINUE READING
Highly Cited
This paper has 141 citations. REVIEW CITATIONS
Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 82 extracted citations

142 Citations

01020'01'04'08'12'16
Citations per Year
Semantic Scholar estimates that this publication has 142 citations based on the available data.

See our FAQ for additional information.